But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.